The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...

Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would ...

GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...

The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...